RESUMEN
STATEMENT OF PROBLEM: Custom healing abutments made of flowable composite resin have gained popularity, although the soft tissue response to composite resin has not been adequately studied. PURPOSE: The purpose of this randomized controlled clinical trial was to evaluate the soft tissue response to titanium stock healing abutments and custom composite resin healing abutments by assessing clinical indices and the level of matrix metalloproteinase-8 (MMP-8) in the peri-implant crevicular fluid (PICF). MATERIAL AND METHODS: A randomized controlled clinical trial was performed on 42 osseointegrated implants. The implants were divided into 2 groups: a test group comprising 21 custom composite resin healing abutments that were attached to the implants at second stage surgery and a control group comprising 21 stock titanium healing abutments. Plaque index (PL), bleeding on probing (BOP), modified gingival index (MGI), and level of MMP8 were measured at the second and fourth week after second stage surgery. Peri-implant crevicular fluid was collected by paper points at each follow-up, and the level of MMP8 was measured by an enzyme-linked immunosorbent assay kit. For statistical analysis, group comparisons used the Mann-Whitney U test, and comparisons within each group at 2 and 4 weeks used the Wilcoxon Sign Rank test. Group differences were analyzed with the Fisher exact test, and the McNemar test was used to compare percentages at 2 and 4 weeks. All tests were two-tailed (α=.05). RESULTS: For the PI, no statistically significant differences were found within groups or between groups (P>.05). Bleeding on probing was positive in 14.3% of titanium abutments versus 20% of composite resin abutments at 4 weeks, with no significant difference between groups (P>.05). Similarly, the mean MGI was 0.38 ±0.5 in the control group while it was 0.4 ±0.5 in the test group, with no significant differences between groups (P>.05). The MMP8 level at 2 weeks was 11.1 ±8.65 and 13.11 ±9.29 for the control and test groups, respectively while it was 16.35 ±8.31 and 19.80 ±8.44 at 4 weeks, showing a statistically significant increase within groups (P<.05). No significant difference between groups was detected at either follow-up time point regarding MMP8 level (P>.05). CONCLUSIONS: The clinical and biochemical soft tissue response to composite resin healing abutments and titanium stock healing abutments were comparable, suggesting the clinical safety of custom composite resin healing abutments.
RESUMEN
OBJECTIVES: The aim of this research was to assess both clinically and histologically the effect of a topically applied melatonin-loaded gelatin sponge on palatal wound healing after graft harvesting. METHODS: Twenty-six patients for whom free palatal graft procurement was indicated were divided equally into 2 groups. In the test group, the donor site was covered by a melatonin-loaded gelatin sponge, and in the control group the site was covered by a placebo-loaded gelatin sponge. Wound healing was evaluated on the day of surgery and at 7 and 14 days postsurgery using photo-digital planimetry. Histologic specimens were taken to verify healing type and rate. Pain was assessed via Visual Analogue Scale (VAS) for 7 days from the day of the surgery. RESULTS: At the 7-day interval, photo-digital planimetry showed a significant decrease in the traced raw area (P = .04) in the test group compared with the control group and a significant increase in the mean area of immature epithelia (P = .04). At the 14-day interval, there was no statistically significant difference in any area of interest. Histologically, the application of melatonin was associated with accelerated healing and superior maturation at all follow-up time points. No significant differences were noted in VAS scores between the 2 groups. CONCLUSIONS: Melatonin-treated tissue showed marked clinical improvement in the first week postsurgery, indicating an increased rate of healing. Similarly, histologic analysis revealed significant maturation at both time intervals. A melatonin-loaded gelatin sponge is a novel palatal wound dressing that can be used to improve wound healing outcomes and reduce patient morbidity.
RESUMEN
BACKGROUND: Oral lichen planus (OLP) is a chronic illness of immune origin that is typically treated with corticosteroids as a gold standard therapy. Photobiomodulation (PBM) may represent an alternative remedy that has the potential to treat a variety of pathological conditions by alleviating pain, reducing inflammation, and promoting tissue healing without the drawbacks of steroid therapies. Thus, the aim of the current study was to compare the effect of photobiomodulation to topical 0.1% triamcinolone acetonide on erosive oral lichen planus. METHODS: This randomized controlled clinical trial involved 44 patients complaining of erosive oral lichen planus. Patients were assigned to one of two groups: control group (n = 22) received 0.1% topical triamcinolone acetonide three times daily with miconazole oral gel once daily for 4 weeks, and photobiomodulation group (n = 22) received laser therapy by 980 nm diode laser utilizing output power 300 mW twice weekly for 5 weeks (a total of 10 sessions). The evaluation of patients was performed at baseline, 6 weeks, and 12 weeks postoperatively in terms of pain, clinical scores, and biochemical evaluation of salivary malondialdehyde levels. All recorded data were analyzed using Mann-Whitney test to compare the two studied groups regarding pain, lesion size, and salivary levels of malondialdehyde. Friedman test, followed by post hoc test, was used for comparison of the data within the same group along the 3 periods at baseline, 6 weeks, and 12 weeks. RESULTS: Both groups showed significant improvement in pain and clinical scores, with no statistical difference between them. Moreover, there was a significant improvement in salivary malondialdehyde levels for both groups, with no significant difference between them. CONCLUSIONS: Photobiomodulation could be a promising therapeutic modality for management of erosive oral lichen planus without the side effects of steroid therapy. The salivary malondialdehyde level could be used as a biomarker to evaluate the disease severity and its response to the treatment. TRIAL REGISTRATION: The study has been registered at ClinicalTrials.gov (NCT05951361) (19/07/2023).